Last reviewed · How we verify
JR-131
JR-131 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to treat FGFR-driven cancers.
JR-131 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to treat FGFR-driven cancers. Used for FGFR-altered solid tumors (in clinical development).
At a glance
| Generic name | JR-131 |
|---|---|
| Sponsor | Kissei Pharmaceutical Co., Ltd. |
| Drug class | FGFR inhibitor |
| Target | FGFR (Fibroblast Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
JR-131 selectively inhibits fibroblast growth factor receptors, which are frequently dysregulated in various solid tumors through mutations, amplifications, or translocations. By blocking FGFR-mediated signaling pathways, the drug suppresses tumor cell proliferation and survival in FGFR-dependent malignancies. This mechanism is particularly relevant in cancers with FGFR alterations where the pathway drives oncogenic growth.
Approved indications
- FGFR-altered solid tumors (in clinical development)
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) (PHASE3)
- A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |